Related Experiment Video
Updated: Jun 26, 2026
Analysis of Retinoic Acid-induced Neural Differentiation of Mouse Embryonic Stem Cells in Two and Three-dimensional Embryoid Bodies
Published on: April 22, 2017
Novel miRNA-inducing drugs enable differentiation of retinoic acid-resistant neuroblastoma cells
Abstract:
Tumor cell heterogeneity in neuroblastoma, a pediatric cancer arising from neural crest-derived progenitor cells, poses a significant clinical challenge. In particular, unlike adrenergic (ADRN) neuroblastoma cells, mesenchymal (MES) cells are resistant to chemotherapy and retinoid therapy and thereby significantly contribute to relapses and treatment failures. Previous research suggested that overexpression or activation of miR-124, a neurogenic microRNA with tumor suppressor activity, can induce the differentiation of retinoic acid-resistant neuroblastoma cells. Leveraging our established screen for miRNA-modulatory small molecules, we validated PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, as a robust inducer of miR-124. A combination of PP121 and BDNF-activating bufalin synergistically arrests proliferation, induces differentiation, and maintains the differentiated state of MES SK-N-AS cells for 8 weeks. RNA-seq and deconvolution analyses revealed a collapse of the ADRN core regulatory circuitry (CRC) and the emergence of novel CRCs associated with chromaffin cells and Schwann cell precursors. Using a similar protocol, we differentiated and maintained MES neuroblastoma GI-ME-N and SH-EP cell lines, as well as glioblastoma LN-229 and U-251 cell lines, for over 16 weeks. In conclusion, our novel protocol suggests a promising treatment for therapy-resistant cancers of the nervous system. Moreover, these long-lived, differentiated cells provide valuable models for studying mechanisms underlying differentiation, maturation, and senescence.
Insights
A novel therapeutic protocol effectively differentiates therapy-resistant mesenchymal neuroblastoma cells. This approach, using PP121 and bufalin, shows promise for treating resistant nervous system cancers.
Area of Science:
- Oncology
- Molecular Biology
- Developmental Neuroscience
Background:
- Neuroblastoma exhibits tumor cell heterogeneity, with mesenchymal (MES) cells showing resistance to standard therapies.
- Mesenchymal neuroblastoma cells contribute significantly to treatment failure and relapse.
- miR-124, a neurogenic microRNA, has demonstrated tumor suppressor activity and can induce differentiation in resistant neuroblastoma cells.
Purpose of the Study:
- To identify and validate small molecules that induce miR-124 expression.
- To develop a therapeutic strategy for overcoming chemoresistance in neuroblastoma.
- To investigate the effects of novel compounds on neuroblastoma cell differentiation and regulatory circuitry.
Main Methods:
- Screening for miRNA-modulatory small molecules to identify miR-124 inducers.
- Utilizing PP121, a dual tyrosine and phosphoinositide kinase inhibitor, to enhance miR-124 levels.
- Combining PP121 with bufalin (a BDNF-activating agent) to treat mesenchymal neuroblastoma cells (SK-N-AS).
- Employing RNA-sequencing and deconvolution analyses to study changes in core regulatory circuitry (CRC).
Main Results:
- PP121 was validated as a potent inducer of miR-124.
- The combination of PP121 and bufalin synergistically arrested proliferation and induced differentiation in MES SK-N-AS cells, maintaining the state for 8 weeks.
- RNA-seq and deconvolution analyses revealed a collapse of the adrenergic (ADRN) CRC and the emergence of new CRCs resembling chromaffin cells and Schwann cell precursors.
- The protocol successfully differentiated and maintained other neuroblastoma and glioblastoma cell lines for over 16 weeks.
Conclusions:
- A novel protocol combining PP121 and bufalin offers a promising treatment strategy for therapy-resistant neuroblastoma and other nervous system cancers.
- The differentiated, long-lived cancer cells generated provide valuable models for studying differentiation, maturation, and senescence mechanisms.
- This approach targets the core regulatory circuitry to overcome treatment resistance in heterogeneous tumors.
Related Concept Videos
01:22MicroRNAs
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
01:10Drugs that Destabilize Microtubules
01:22MicroRNAs